Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit From Immunotherapy – Bioscience Technology
|
Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit From Immunotherapy
Bioscience Technology Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit … |
